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Abstract
Background: Models that accurately predict risk of breast cancer are needed to help younger women make
decisions about when to begin screening. Premenopausal concentrations of circulating anti-Müllerian hormone
(AMH), a biomarker of ovarian reserve, and testosterone have been positively associated with breast cancer risk in
prospective studies. We assessed whether adding AMH and/or testosterone to the Gail model improves its prediction
performance for women aged 35–50.
Methods: In a nested case-control study including ten prospective cohorts (1762 invasive cases/1890 matched controls)
with pre-diagnostic serum/plasma samples, we estimated relative risks (RR) for the biomarkers and Gail risk factors using
conditional logistic regression and random-effects meta-analysis. Absolute risk models were developed using these RR
estimates, attributable risk fractions calculated using the distributions of the risk factors in the cases from the consortium,
and population-based incidence and mortality rates. The area under the receiver operating characteristic curve (AUC) was
used to compare the discriminatory accuracy of the models with and without biomarkers.
Results: The AUC for invasive breast cancer including only the Gail risk factor variables was 55.3 (95% CI 53.4, 57.1). The
AUC increased moderately with the addition of AMH (AUC 57.6, 95% CI 55.7, 59.5), testosterone (AUC 56.2, 95% CI 54.4,
58.1), or both (AUC 58.1, 95% CI 56.2, 59.9). The largest AUC improvement (4.0) was among women without a family
history of breast cancer.
Conclusions: AMH and testosterone moderately increase the discriminatory accuracy of the Gail model among women
aged 35–50. We observed the largest AUC increase for women without a family history of breast cancer, the group that
would benefit most from improved risk prediction because early screening is already recommended for women with a
family history.
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Background
Breast cancer risk prediction models can help women
and their health providers make decisions about screen-
ing and chemoprevention. While women aged 50 are
uniformly included in mammographic screening recom-
mendations, the guidelines regarding at what age to start
screening are inconsistent, varying from age 40 to 50,
particularly for women without a family history of breast
cancer (https://www.uspreventiveservicestaskforce.org/
Page/Document/UpdateSummaryFinal/breast-cancer-scr
eening1 [1–7]). Improvements in individualized risk as-
sessment would therefore be particularly valuable for
women younger than 50 to decide when to start mam-
mographic screening. A risk prediction model with high
accuracy could also help women decide whether to take
tamoxifen for breast cancer prevention. Younger women
are more likely to benefit from tamoxifen than older
women because they have lower risks of tamoxifen-re-
lated adverse events [8–13]. Nonetheless, an accurate es-
timate of risk of breast cancer is critical in calculating
the benefit-risk index for these women.
The Gail model 2 [14] is the most widely studied
breast cancer risk prediction model for women without
a strong family history of breast cancer or an inherited
mutation associated with high susceptibility. The breast
cancer risk factors in the model are age, age at menar-
che, age at first live birth, number of previous breast bi-
opsies, history of atypical hyperplasia, and first-degree
family history of breast cancer [14]. The Gail model 2
was initially developed using data from white women,
and race/ethnicity-specific adaptations of the model
were subsequently developed. The model was imple-
mented in the National Cancer Institute’s Breast Cancer
Risk Assessment Tool (BCRAT) which is available on-
line. The model has been validated in studies in the USA
and several Western European countries, including stud-
ies of younger women [15–23]. It has been shown in
most studies to be well calibrated [14, 15, 23], i.e., it pre-
dicts fairly accurately the number of women who will
develop breast cancer overall and in subgroups defined
by risk factors. However, the model has limited discrim-
inatory accuracy, i.e., it does not separate well women
who subsequently develop cancer from those who do
not [15].
We recently showed that the premenopausal circulat-
ing concentration of anti-Müllerian hormone (AMH), a
marker of ovarian reserve, is associated with risk of
breast cancer [24]. Circulating testosterone concentration,
measured before [25–30] or after menopause [31–38], has
also been consistently associated with breast cancer risk.
AMH and testosterone are fairly stable during the men-
strual cycle and temporal reliability studies have shown
that a single measurement of AMH or testosterone can be
used to rank premenopausal women with regard to their
average hormone level over a several-year period with rea-
sonable accuracy [25, 34, 39–42]. They are also relatively
inexpensive to measure. Thus, these two hormones are
good candidate biomarkers for inclusion in breast cancer
risk prediction models for younger women, who have
large fluctuations in other hormone-related biomarkers
during the menstrual cycle.
The objective of this study was to evaluate whether
adding circulating AMH and/or testosterone measure-
ments to the Gail model improves its discriminatory ac-
curacy among women aged 35–50.
Methods
Study subjects
Participants in a nested case-control study in a consor-
tium of ten prospective cohorts from the USA, UK, Italy,
and Sweden [24] were included in this study. The parent
cohorts were the Generations Study (BGS); CLUE II;
Columbia, MO Serum Bank (CSB); Guernsey Cohort;
New York University Women’s Health Study (NYUWHS);
Nurses’ Health Studies (NHS) I and II; Northern Sweden
Mammary Screening Cohort (NSMSC); Hormones and
Diet in the Etiology of Breast Cancer (ORDET); and the
Sister Study (Sister). A brief description of the cohorts can
be found in Ge et al. [24]. Each cohort was approved by
its institutional review board, and informed consent was
obtained from each participant.
Incident breast cancer cases were ascertained by each
cohort through self-report on follow-up questionnaires
and/or linkages with local, regional, or national cancer
registries. All cases of incident invasive breast cancer di-
agnosed among women who were 35–50 at the time of
blood donation were included except in the NHS co-
horts, which further limited case selection to women
who were premenopausal and between the ages of 35–
50 at diagnosis. Controls were selected within each co-
hort using incidence density sampling. One control was
selected for each case (except for the Sister Study, which
matched 1:2). Matching variables included age and date
of blood donation, and race/ethnicity [24]. Many of the
cohorts matched on additional variables, for example,
phase or day of menstrual cycle and technical sample
characteristics, such as time between collection and pro-
cessing. Women who were ever users of hormone ther-
apy (HT) or current users of oral contraceptives (OCs)
were excluded.
Laboratory measurements
AMH was measured in serum or plasma samples from
women who were premenopausal at the time of blood
donation using the picoAMH assay (ANSH laboratories)
[24]. Women who had AMH concentrations below the
lowest detectable value (LDV) (< 10% of samples for
eight cohorts and < 20% for the remaining two cohorts)
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were classified into the lowest quartile for analyses (see
“Statistical methods”). Because it has previously been
shown that postmenopausal women have AMH concen-
trations below the LDV [43, 44], we did not measure
AMH in postmenopausal women (23 cases and 40 con-
trols) but also classified them into the lowest quartile.
Total testosterone was measured for all subjects in
CLUE II, NHS, and NSMSC and for the matched sets
for which it was not measured previously for the other
cohorts. Measurements were done in the Immunochem-
ical Core Laboratory of the Mayo Clinic by liquid chro-
matography-tandem mass spectrometry (LC-MS/MS).
Assay coefficients of variation (CVs) were calculated using
blinded quality control samples. For AMH, the mean
intra-batch CV was 5.1% and the inter-batch CV was
21.4%. For testosterone, all intra- and inter-batch CVs
were ≤ 10.6%. Previous testosterone measurements were
performed as described in [25, 26, 29, 45–48].
Statistical methods
Relative risk estimation
We estimated cohort-specific relative risks (RRs) associ-
ated with the breast cancer risk factors included in the
Gail model and with each of the biomarkers (testoster-
one and AMH) using conditional logistic regression
(odds ratio estimates are referred to throughout as
relative risks (RRs), by convention). Cohort-specific
RRs were combined to obtain consortium-wide RR
estimates using the random-effects meta-analytic method.
I2 and Q-tests were used to test for heterogeneity across
cohorts.
We used the same coding as the BCRAT for age at
menarche (< 12 years, 12 to 13, or ≥ 14) and age at first
live birth (< 20, 20 to 24, 25 to 29/nulliparous, or ≥ 30
years) [14]. Family history of breast cancer was coded
using a three-category variable (0/1/> 1 affected rela-
tive(s)). For cohorts that collected family history as a
yes/no variable, women who responded yes were in-
cluded in the intermediate category (1 affected relative).
History of breast biopsy was coded as yes/no. We did
not include an interaction between breast biopsy and
age (< 50/≥ 50 years) because this study was restricted to
younger women (≤ 50). The interaction term between
age at first birth and number of affected relatives was
not statistically significant for any cohort and thus not
included in the model. To be consistent with BCRAT,
which imputes missing data to the lowest risk category,
we imputed missing data as follows: age at menarche: ≥
14 for 35 cases (1.5%) and 49 controls (1.9%); age at first
live birth: < 20 for 5 cases (0.2%) and 7 (0.3%) controls;
and number of breast biopsies: 0 for 42 cases (1.8%) and
40 controls (1.6%). Data on history of atypical hyperpla-
sia were not available from any of the cohorts and this
variable was set to the lowest risk category as is the case
when “unknown” is entered in the BCRAT. Because we
could not exclude the possibility that cohort differences
in the AMH and testosterone concentration distribu-
tions were related to collection/handling/storage of sam-
ples [24], biomarkers were categorized into quartiles
using cohort-specific cutpoints and modeled as ordered
categorical variables.
Absolute risk estimation
We used the method described by Gail et al. [22, 49] to
estimate the 5-year absolute breast cancer risk for each
participant. We used consortium-wide estimates of RRs
for the Gail variables and biomarkers (calculated as de-
scribed above), consortium-based estimates of attribut-
able risk fractions, and population-based breast cancer
incidence and mortality rates. Attributable risk fractions
were estimated using consortium-wide RR estimates and
distributions of the Gail variables and biomarkers in the
cases (excluding the Sister Study because all women in
this study had a family history of breast cancer) [49].
Breast cancer incidence and competing mortality (i.e.,
non-breast cancer mortality) rates were obtained from
the countries of the participating cohorts (US, UK, Italy,
and Sweden) for the relevant 5-year age categories
(35–39, 40–44, 45–49) and calendar years of blood
collection (Additional file 1: Table S1).
For comparison, we also calculated the 5-year absolute
risks of developing breast cancer using the BCRAT SAS
macro (available at: https://dceg.cancer.gov/tools/risk-as-
sessment/bcrasasmacro), which uses US population-
based RR estimates [8, 14, 15, 22]. We refer to results
using these calculations as “BCRAT” (to distinguish
them from results based on RRs estimated from our
dataset, called “Gail model”).
Assessment of discriminatory accuracy
We estimated the area under the receiver operating
characteristic curve (AUC) based on the 5-year absolute
risk estimates from the BCRAT, the Gail model, and the
Gail model with addition of AMH and/or testosterone.
Summary AUCs were estimated from the cohort-specific
AUCs using random-effects meta-analytic methods.
AUCs were also estimated within subgroups, i.e., by age,
estrogen receptor (ER) status of the tumor, and Gail risk
score (< 1%/≥ 1%), and for women without a family his-
tory of breast cancer. AUCs are expressed throughout as
percentages (AUC × 100) for ease of interpretation. Fi-
nally, we assessed reclassification of 5-year absolute risks
upon addition of biomarkers.
Results
Descriptive characteristics of the cases and controls are
shown in Table 1. By design, women were between the
ages of 35–50 at blood donation. About 40% of cases
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Table 1 Descriptive characteristics of invasive breast cancer cases
and matched controls
Cases (n = 1762) Controls (n = 1890)
Cohort, n
BGS 230 230
CLUE II 87 87
CSB 69 69
Guernsey 124 124
NHS 93 93
NHS II 248 250
NSMSC 31 31
NYUWHS 493 496
ORDET 214 224
Sister 173 286
Age at blood donation, years, n (%)
35–40 472 (26.8) 487 (25.8)
41–45 708 (40.2) 752 (39.8)
46–50a 582 (33.0) 651 (34.5)
Race/ethnicity, n (%)
White 1587 (90.1) 1696 (89.7)
Black/African American 76 (4.3) 73 (3.9)
Other or missing 99 (5.6) 121 (6.4)
Age at diagnosis, years, n (%)
35–45 287 (16.3)
46–50 579 (32.9)
51–55 436 (24.7)
56–60 235 (13.3)
61–65 141 (8.0)
> 65 84 (4.8)
Lag time between blood donation and diagnosis, years, n (%)
0–2 274 (15.6)
3–5 420 (23.8)
6–10 443 (25.1)
11–15 286 (16.2)
16–20 201 (11.4)
> 20 138 (7.8)
Age at menarche, years, n (%)
< 12 376 (21.3) 411 (21.7)
12–13 976 (55.4) 1012 (53.5)
≥14 or missingb 410 (23.3) 467 (24.7)
Age at first live birth, years, n (%)
< 20 or missingb 114 (6.5) 143 (7.6)
20–24 457 (25.9) 521 (27.6)
25–29c 473 (26.8) 511 (27.1)
≥ 30 304 (17.3) 307 (16.2)
Nulliparous 414 (23.5) 408 (21.5)
Table 1 Descriptive characteristics of invasive breast cancer cases
and matched controls (Continued)
Cases (n = 1762) Controls (n = 1890)
Number of benign breast biopsies, n (%)
0 or missingb 1339 (76.0) 1559 (82.5)
≥ 1 423 (24.0) 331 (17.5)
0 1311 (74.4) 1415 (74.9)
1d 382 (21.7) 412 (21.8)
> 1d 69 (3.9) 63 (3.3)
BMI, kg/m2, n (%)
< 25 1097 (59.9) 1124 (62.6)
25–29 420 (24.8) 465 (24.0)
≥ 30 234 (15.4) 289 (13.4)
Missing 11 12
AMH cohort-specific quartiles, n(%)
Q1 365 (20.7) 480 (25.4)
Q2 444 (25.1) 468 (24.8)
Q3 453 (25.7) 468 (24.8)
Q4 500 (28.4) 474 (25.1)
Testosterone cohort-specific quartiles, n (%)
Q1 423 (24.0) 511 (27.0)
Q2 414 (23.5) 464 (24.6)
Q3 452 (25.7) 460 (24.3)
Q4 473 (26.8) 455 (24.1)
BCRAT 5-year risk score (%), n (%)e
< 0.6% 296 (16.8) 332 (17.6)
0.6–0.99% 679 (38.5) 765 (40.5)
1–1.66% 525 (29.8) 517 (27.3)
1.67–1.99% 110 (6.2) 130 (6.9)
2–2.99% 115 (6.5) 115 (6.1)
≥ 3% 37 (2.1) 31 (1.6)
ER status, n (%)
ER-positive 1139 (79.8)
ER-negative 289 (20.2)
Unknown 334
Note: Cases and controls were matched 1:1 for all cohorts except for Sister
Study which matched 1:2
aAll cases had age at blood donation ≤ 50, though for 24 sets, matched
controls ages were ≤ 51.2 years at blood donation
bTo be consistent with BCRAT, which imputes missing data to the lowest risk category,
we imputed missing data as follows: age at menarche: ≥ 14 for 35 cases (1.5%) and 49
controls (1.9%); age at first live birth: < 20 for 5 cases (0.2%) and 7 (0.3%) controls;
number of breast biopsies: 0 for 42 cases (1.8%) and 40 controls (1.6%)
cAs done in BCRAT, nulliparous and women who were 25–29 at first birth were
combined in all models
dThe number of first-degree family members with breast cancer was coded as 0, 1,
or > 1 affected relatives. For cohorts that collected family history as a no/yes variable,
“yes” answers were assigned to the intermediate category (1 affected relative)
eCalculated using the following variables: race, age at menarche, age at first
live birth, number of breast biopsies, and number of first-degree family
members with breast cancer, history of atypical hyperplasia was missing for
all cohorts and set to “no.” Gail model 2 rates and parameters were used as
described in [14]
Clendenen et al. Breast Cancer Research           (2019) 21:42 Page 4 of 12
donated blood samples in the 5 years preceding breast
cancer diagnosis. Consistent with known breast cancer
risk factor associations, cases were more likely than con-
trols to have had a breast biopsy, to have a family history
of breast cancer, and to be nulliparous or have had their
first live birth after age 30. The vast majority of women
had low to average BCRAT 5-year risk scores (over half
of the women had a risk < 1%), as expected in a study of
younger women.
Table 2 shows the RR estimates for invasive breast
cancer associated with Gail model risk factors and bio-
markers. The RRs for the Gail model variables did not
change appreciably with the addition of biomarkers to
the model. When individually added to the Gail model,
AMH was associated with a 55% increase in risk and tes-
tosterone with a 27% increase in risk for the 4th vs. 1st
quartiles; when added together, AMH was associated
with a 53%, and testosterone with a 22%, increase.
Table 2 also shows the attributable risk fraction esti-
mates for each unit increase in risk factor or biomarker.
For Gail model variables, the risk attributable to age at
menarche was low (< 1%), while attributable risks were
higher for family history of breast cancer (7%), history of
breast biopsy (8%), and age at first pregnancy (18%). The
attributable risk for a one-quartile increase in AMH was
19% and for testosterone 9%. In a sensitivity analysis re-
stricted to the five US cohorts included in our study, the
attributable risks calculated using US population risk
factor distributions were similar to estimates based on
risk factor distributions in the cases (data not shown)
[22, 49–51]. Cohort-specific RR estimates for invasive
breast cancer from the model including both biomarkers
Table 2 Relative risks calculated using random-effects meta-analysis and attributable risk fractions
Risk factor RR estimates Attributable risk (%) for
Gail+ AMH + testosterone
modelb
Gail Gail + AMH Gail + testosterone Gail + AMH + testosterone
Age at menarche, years 0.67%
< 12 1.00 (0.90, 1.11) 1.02 (0.91, 1.13) 1.00 (0.90, 1.11) 1.01 (0.91, 1.12)
12–13 1.00 (0.90, 1.11) 1.01 (0.91, 1.12) 1.00 (0.90, 1.11) 1.01 (0.91, 1.12)
≥ 14 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref)
Age at first live birth, years 18.47%
< 20 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref)
20–24 1.11 (1.00, 1.24) 1.12 (1.00, 1.25) 1.12 (1.00, 1.26) 1.12 (1.00, 1.26)
25–29 or nulliparous 1.24 (1.11, 1.38) 1.25 (1.12, 1.39) 1.26 (1.12, 1.41) 1.26 (1.13, 1.42)
≥ 30 1.38 (1.23, 1.54) 1.40 (1.25, 1.56) 1.41 (1.26, 1.58) 1.42 (1.27, 1.60)
Number of benign breast biopsies 8.13%
0 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref)
≥ 1 1.58 (1.33, 1.88) 1.55 (1.31, 1.85) 1.59 (1.34, 1.89) 1.56 (1.31, 1.86)
Number of first-degree family members with breast cancera 6.56%
0 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref)
1 1.58 (1.32, 1.89) 1.57 (1.31, 1.88) 1.57 (1.30, 1.88) 1.56 (1.30, 1.87)
> 1 2.49 (2.08, 2.99) 2.47 (2.06, 2.96) 2.45 (2.04, 2.94) 2.43 (2.03, 2.92)
AMH 19.38%
Q1 – 1.0 (ref) – 1.0 (ref)
Q2 – 1.16 (1.04, 1.29) – 1.15 (1.03, 1.28)
Q3 – 1.34 (1.20, 1.49) – 1.33 (1.19, 1.48)
Q4 – 1.55 (1.39, 1.73) – 1.53 (1.37, 1.70)
Testosterone 9.48%
Q1 – – 1.0 (ref) 1.0 (ref)
Q2 – – 1.08 (1.02, 1.15) 1.07 (1.00, 1.14)
Q3 – – 1.17 (1.10, 1.25) 1.14 (1.07, 1.22)
Q4 – – 1.27 (1.19, 1.35) 1.22 (1.15, 1.30)
aThe number of first-degree family members with breast cancer was coded as either 0, 1, or > 1 affected relatives. For cohorts that collected family history as a
no/yes variable, “yes” answers were assigned to the intermediate category (1 affected relative)
bWe used the method described in Bruzzi et al. [49] to estimate attributable risk for a one-category increase (or decrease for age at menarche) in the risk factor.
The Sister study was excluded from attributable risk estimation because all participants had a family history of breast cancer
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are shown in Additional file 1: Figure S1. Tests for het-
erogeneity by cohort were not statistically significant.
Removing one cohort at a time from the analysis did not
change the RRs appreciably (data not shown).
Figure 1 and Table 3 show the AUCs based on
BCRAT, the Gail model, and the Gail model with bio-
markers. The summary AUC for invasive breast cancer
using the BCRAT was 55.0 (95% CI 53.1, 56.8). The
AUC in our implementation of the Gail model was very
similar (AUC 55.3, 95% CI 53.4, 57.1). The AUC in-
creased with the addition of AMH (AUC 57.6, 95% CI
55.7, 59.5), testosterone (AUC 56.2, 95% CI 54.4, 58.1),
and both AMH and testosterone (AUC 58.1, 95% CI
56.2, 59.9). The percent increase relative to the Gail
model was statistically significant for the model includ-
ing AMH (4.2%, p = 0.007) and the model including both
AMH and testosterone (5.1%, p = 0.001), but not testos-
terone alone (1.6%, p = 0.086). AUCs were similar when
Fig. 1 Area under the receiver operating curve (AUC) estimates and 95% confidence intervals
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both in situ and invasive cases were considered together
(Additional file 1: Figure S4).
Table 3 also shows AUCs in subgroups. Small im-
provements in AUCs with the addition of both bio-
markers to the Gail model were observed in each
age-at-blood-donation subgroup, with the largest in-
crease (3.5, a relative increase of 6.0%) for women ages
45–50, for whom the Gail model also had the highest
AUC (58.6). AUC improvements for women with a
5-year risk lower than 1% were greater (3.0, a relative in-
crease of 5.7%) than those for women with risk of at
least 1% (1.0, a relative increase of 1.7%). AUC improve-
ment was larger for ER-positive tumors (2.8, a relative
increase of 5.0%) than ER-negative tumors (0.3, a relative
increase of 0.5%). We also found that the AUC increased
(4.0, a relative increase of 7.6%) with the addition of
biomarkers for the subgroup of women without a
family history of breast cancer, but less so for women
with a family history (2.2, a relative increase of 4.4%).
Figure 2 shows the histograms displaying absolute
risk estimates of cases and controls for the Gail
model with and without testosterone and AMH.
Though there was substantial overlap between the
distributions in cases and controls, the distribution
was skewed to the right for cases. Adding the bio-
markers resulted in a slight shift of the distribution
to the right for cases (9.3% had risk estimates move
from below to above 1%, while 8.1% moved down,
Table 4) and a slight shift to the left for controls
(8.7% had risk estimates move from below to above
1%, while 10.4% moved down, Table 4).
Discussion
Circulating AMH and testosterone moderately increased
the discriminatory accuracy of the Gail breast cancer
risk prediction model among women ages 35–50 in our
study of 1762 invasive cases and 1890 matched controls.
Discriminatory accuracy improved with the addition of
either AMH or testosterone, though the improvement
was only statistically significant for AMH. In the model
including both biomarkers, we observed an AUC in-
crease from 55.3 to 58.1 (relative increase of 5.1%).
Overall, inclusion of biomarkers tended to moderately
increase 5-year risk estimates for cases and reduce esti-
mates for controls.
The increase in AUC resulting from the addition of
biomarkers was slightly higher in analyses limited to
women without a family history of breast cancer than
that observed in analyses including all women. This is of
interest because the majority of breast cancers occur
among women without a family history. Further, women
without a family history are the group in which improve-
ments in risk prediction could have the most impact,
since it is already recommended that women with a fam-
ily history start screening early (https://www.uspreventi
veservicestaskforce.org/Page/Document/UpdateSummar
yFinal/breast-cancer-screening1).
While risk prediction models applicable to younger
women would be valuable for screening and preventive
treatment decision-making, less work has focused on
this group of women as compared to older women
[52–54]. To our knowledge, risk prediction estimation
has been assessed for premenopausal women from
Table 3 AUCs by subgroups
BCRATa Gailb Gail + AMHb Gail + testosteroneb Gail + AMH + testosteroneb
Total AUC 55.0 (53.1, 56.8) 55.3 (53.4, 57.1) 57.6 (55.7, 59.5) 56.2 (54.4, 58.1) 58.1 (56.2, 59.9)
Age at blood donation, years
≤ 40 55.9 (52.3, 59.6) 56.2 (52.5, 59.8) 57.5 (53.8, 61.1) 57.3 (53.7, 61.0) 58.1 (54.4, 61.8)
41–45 55.2 (52.2, 58.2) 54.9 (51.9, 57.9) 56.3 (53.3, 59.2) 56.0 (53.0, 58.9) 56.6 (53.7, 59.6)
> 45 58.6 (55.4, 61.9) 58.6 (55.3, 61.9) 60.6 (57.4, 63.8) 60.9 (57.7, 64.1) 62.1 (58.9, 65.3)
Gail 5-year risk score, %
< 1c 53.2 (50.2, 55.2) 52.9 (50.4, 55.4) 54.7 (52.2, 57.2) 54.3 (51.8, 56.8) 55.9 (53.4, 58.3)
≥ 1c 56.6 (53.7, 59.5) 58.2 (55.3, 61.0) 59.1 (56.3, 62.0) 57.4 (54.3, 60.5) 59.2 (56.3, 62.1)
Estrogen receptor status
ER-positive 56.1 (53.8, 58.4) 56.4 (54.1, 58.8) 58.9 (56.2, 61.6) 57.2 (54.9, 59.5) 59.2 (56.3, 62.0)
ER-negative 55.8 (51.1, 60.5) 56.8 (52.1, 61.5) 58.0 (53.3, 62.7) 57.1 (52.4, 61.8) 57.1 (52.3, 61.8)
Number of first-degree family members with breast cancer, n (%)
0 52.2 (50.0, 54.3) 52.8 (50.6, 55.0) 55.6 (52.9, 58.3) 54.6 (52.4, 56.8) 56.8 (54.6, 58.9)
≥ 1 55.9 (52.1, 59.6) 55.0 (51.3, 58.7) 57.2 (53.4, 60.9) 56.4 (52.7, 60.1) 57.2 (52.0, 62.4)
aEstimates from the model as implemented in BCRAT and using BCRAT regression coefficients
bModel including Gail model variables and biomarker(s) and using regression coefficients in Table 2
cMedian 5-year absolute risk was approximately 1%
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the general population in six studies [55–60]. Most of
these assessed or modified the Gail model, but some
had extensive missing data for Gail model variables
[55, 57] or did not assess discriminatory accuracy
[57]. Others developed new models for which validation
has not yet been attempted in independent studies
[55, 60]. Testosterone was added to the Gail model in
one study that included premenopausal women [56]. In
this study of 430 cases/684 controls, the addition of hor-
mones, including testosterone, to the Gail model did not
result in any change in the AUC for premenopausal
women [56]. Unlike this study, the increase in AUC that
we observed with the addition of testosterone is in agree-
ment with the premenopausal testosterone-breast cancer
risk association that has been consistently observed
[25–30]. AMH has not been included in breast cancer
risk prediction models previously.
Some studies, though not all [61, 62], have reported
correlations of BMI with testosterone and AMH in pre-
menopausal women [39, 63, 64]. These correlations have
generally been weak, including in our study (Spearman
partial correlations with BMI among controls, adjusted
for cohort and age, were 0.06 for testosterone, and −
0.07 for AMH). This suggests that including BMI in the
model, though it would be easier than including bio-
markers because BMI does not require a blood draw,
would not capture the impact of AMH and testosterone
on breast cancer risk.
The AUC increases with the addition of AMH, and
testosterone were greater for ER-positive than ER-nega-
tive tumors, as expected since AMH was more strongly
associated with risk of ER-positive than ER-negative tu-
mors in our study [24]. Though AMH and estrogen con-
centrations are not strongly correlated in premenopausal
women [39, 64], AMH is strongly associated with age at
Fig. 2 Reclassification of absolute 5-year risk of breast cancer with the addition of AMH and testosterone to the Gail model
Table 4 Absolute risk reclassification upon adding AMH and
testosterone to the Gail model
Gail + AMH +
testosterone
5-year risk
Moved
up (%)
Moved
down (%)
Reclassification in cases < 1% ≥ 1%
Gail 5-year risk < 1% 588 163
≥ 1% 143 868
9.3% 8.1%
Reclassification in controls < 1% ≥ 1%
Gail 5-year risk < 1% 708 165
≥ 1% 196 821
8.7% 10.4%
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menopause, at which time estrogen exposure decreases.
This association may explain the greater improvement
in prediction of estrogen-sensitive tumors than
ER-negative tumors with the inclusion of AMH in the
Gail model.
Several other risk factors have been proposed for in-
clusion in the Gail model to improve discriminatory ac-
curacy, with varying applicability to premenopausal
women. Mammographic density has been shown to in-
crease the discriminatory accuracy of the Gail model in
several studies [51, 55, 65, 66], but density is not avail-
able yet to women deciding when to begin screening.
Endogenous hormones other than AMH and testoster-
one, such as estrogen, progesterone, and prolactin, fluc-
tuate during the menstrual cycle and/or are not
consistently associated with risk in premenopausal
women [31, 67]. Common, low-penetrance genetic risk
factors may also have utility for risk prediction in
younger women. Single nucleotide polymorphisms
(SNPs), and their combined risk scores (ranging from
6 to 77 SNPs across studies), have increased Gail
model AUCs (AUC increases of 0.6–7.0) in most
studies [54, 59, 68–75], including among younger
women [59]. Inclusion of a 77-SNP score increased
the AUC from 0.64 to 0.66 among women < 50 years
of age [59], an increase comparable to that observed
with the addition of AMH and testosterone. Because
most genetic variants that are associated with breast
cancer risk are not in hormone-related genes, they
are likely to contribute to risk prediction independ-
ently of AMH and testosterone. Thus, models includ-
ing both genetic variants and hormone biomarkers as
a panel may perform better than models including
only one type of marker.
We could not directly assess the calibration of the
model including biomarkers because AMH and testos-
terone were measured only in matched case-control sets;
thus, the expected number of cases in the full cohorts
using the model including biomarkers could not be esti-
mated [76]. Another method to indirectly assess calibra-
tion is inverse probability weighting [77], which uses the
probability of being selected into the nested case-control
study as a weighting factor to estimate the expected
number of cases in the cohort. However, closely matched
nested case-control studies, as in this consortium, yield
high selection probabilities for a substantial proportion of
controls because the risk sets from which controls are se-
lected can be very small. For example, for the 496 controls
in the NYUWHS, we would expect an average selection
probability of ~ 10% (5600 cohort participants were be-
tween the ages of 35 and 50 at enrollment), but the aver-
age probability was 35%. The controls in this study
provided insufficient information about the full cohort,
precluding the assessment of calibration [76].
Our study included past users of oral contraceptives
(> 65%) [24], but not current users because AMH levels
go down during oral contraceptive use [62, 78, 79].
Thus, our results only apply to women not on oral
contraceptives.
In addition to the large size of our study, its major
strength is the prospective design. Samples collected
prior to diagnosis are valuable for measuring biomarkers
that can be affected by the diagnosis and/or treatment of
breast cancer. Another strength is that detailed epi-
demiological data on breast cancer risk factors were col-
lected from all cohorts.
Conclusions
In conclusion, we observed moderate increases in the
discriminatory accuracy of the Gail model 2 for women
aged 35–50 with the addition of AMH and testosterone.
Combining these markers with others (e.g., SNPs) may
improve risk prediction models, though the improve-
ment in discriminatory accuracy will remain limited
until new markers with stronger associations with breast
cancer risk are identified [80, 81].
Additional file
Additional file 1: Table S1. Breast cancer incidence and competing
mortality rates used for each cohort to estimate absolute risk. Table S2.
Descriptive characteristics of invasive + in situ cases and matched controls.
Table S3. Descriptive characteristics of invasive breast cancer cases and
matched controls, by cohort. Table S4. Descriptive characteristics of
invasive plus in situ breast cancer cases and matched controls, by cohort.
Table S5. Random-effects meta-analysis relative risk estimates, invasive and
in situ. Figure S1. Cohort-specific and random-effects meta-analysis relative
risk estimates for Gail model variables, AMH and testosterone (invasive cases
only). Figure S2. Cohort-specific and random-effects meta-analysis relative
risk estimates for Gail model variables, AMH and testosterone, invasive and
in situ. Figure S3. Relative risk estimates by age group, invasive cases only.
Figure S4. AUCs by cohort 95% confidence intervals, invasive and in situ.
(DOCX 254 kb)
Abbreviations
AMH: Anti-Müllerian hormone; AUC: Area under the receiver operating
characteristic curve; BCRAT: Breast Cancer Risk Assessment Tool; BGS: The
Generations Study; BMI: Body mass index; CSB: Columbia, MO Serum Bank;
CV: Coefficient of variation; ER: Estrogen receptor; LDV: Lowest detected
value; NHS: Nurses’ Health Study; NSMSC: Northern Sweden Mammary
Screening Cohort; NYUWHS: New York University Women’s Health Study;
ORDET: Hormones and Diet in the Etiology of Breast Cancer; RR: Relative
risk
Acknowledgements
We thank the NCI Cohort Consortium. CLUE authors would like to thank the
State of Maryland, the Maryland Cigarette Restitution Fund, and the National
Program of Cancer Registries of the Centers for Disease Control and
Prevention for the funds that helped support the collection and availability of
the cancer registry data. The CLUE authors would also like to thank the CLUE
participants and staff at the George W. Comstock Center for Public Health
Research and Prevention. NHS authors thank the participants and staff of the
NHS and NHSII for their valuable contributions as well as the following state
cancer registries for their help: AL, AZ, AR, CA, CO, CT, DE, FL, GA, ID, IL, IN, IA,
KY, LA, ME, MD, MA, MI, NE, NH, NJ, NY, NC, ND, OH, OK, OR, PA, RI, SC, TN, TX,
Clendenen et al. Breast Cancer Research           (2019) 21:42 Page 9 of 12
VA, WA, WY. The authors assume full responsibility for analyses and
interpretation of these data.
Funding
This work was supported by grant NIH R01 CA178949. Support for the
individual cohorts included:
The Generations Study (BGS): This work was supported by Breast Cancer
Now and The Institute of Cancer Research. We acknowledge NHS funding to
the Royal Marsden and The Institute of Cancer Research NIHR Biomedical
Research Centre. Columbia, MO Serum Bank (CSB): This research was
supported by the Intramural Research Program of the NIH, National Cancer
Institute and the Department of Defense Breast Cancer Research Program
(BC062367). Guernsey cohort (Guernsey): Cancer Research UK C570/A16491.
Availability of data and materials: Data access policies for the Guernsey study
are available on the Cancer Epidemiology Unit website at https://www.ceu.
ox.ac.uk/policies2. Nurses’ Health Study (NHS): NCI UM1 CA186107; R01
CA49449. Nurses’ Health Study II (NHSII): NCI UM1 CA176726; R01 CA67262.
New York University Women’s Health Study (NYUWHS): NIH R01 CA098661,
UM1 CA182934 and center grants P30 CA016087 and P30 ES000260. Sister
Study: This research was supported in part by the Intramural Research
Program of the NIH, National Institute of Environmental Health Sciences
(Z01-ES044005) to D.P. Sandler and the Avon Foundation (02–2012-085)
to H.B. Nichols and D.P. Sandler.
Availability of data and materials
All data relevant to this report are included in this published article and its
supplementary information files. The datasets analyzed during the current
study are not publicly available due to protection of participant privacy and
confidentiality but are available in anonymized form from the corresponding
author on reasonable request.
Authors’ contributions
TVC, WG, KLK, AZJ, and ML were involved in the study conception and
design. TVC, WG, KLK, YA, CA, LAB, FD, JFD, AHE, RTF, GH, SHE, JHB, TJK, VK,
HBN, DPS, MJS, PMS, MS, AJS, KV, AZJ, and ML acquired the data and
participated in the interpretation and analysis of data. TVC, WG, KLK, YA, AZJ,
and ML drafted the manuscript. TVC, WG, KLK, YA, CA, LAB, FD, JFD, AHE,
RTF, GH, SHE, JHB, TJK, VK, HBN, DPS, MJS, PMS, MS, AJS, KV, AZJ, and ML
revised the manuscript critically for intellectual content. All authors approve
the final manuscript as submitted.
Ethics approval and consent to participate
Each cohort was approved by its institutional ethical review board.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Department of Population Health, New York University School of Medicine,
650 First Avenue, New York, NY 10016, USA. 2Department of Pathology, New
York University School of Medicine, New York, NY, USA. 3Perlmutter Cancer
Center, New York University School of Medicine, New York, NY, USA.
4Epidemiology and Prevention Unit, Fondazione IRCCS - Istituto Nazionale
dei Tumori, Milan, Italy. 5Division of Cancer Epidemiology and Genetics,
National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
6Department of Epidemiology and Public Health, University of Maryland
School of Medicine, Baltimore, MD, USA. 7Department of Epidemiology,
Harvard T.H. Chan School of Public Health, and Channing Division of
Network Medicine, Brigham and Women’s Hospital, Harvard Medical School,
Boston, MA, USA. 8Department of Biostatistics and Epidemiology, School of
Public Health and Health Sciences, University of Massachusetts, Amherst, MA,
USA. 9Department of Biobank Research, Public Health and Clinical Medicine,
Umeå University, Umeå, Sweden. 10Department of Epidemiology, Johns
Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. 11Sidney
Kimmel Cancer Center, Johns Hopkins School of Medicine, Baltimore, MD,
USA. 12Cancer Epidemiology Unit, Nuffield Department of Population Health,
University of Oxford, Oxford, UK. 13Department of Epidemiology, University of
North Carolina, Chapel Hill, NC, USA. 14Epidemiology Branch, National
Institute of Environmental Health Sciences, Research Triangle Park, NC, USA.
15Division of Genetics and Epidemiology, The Institute of Cancer Research,
London, UK. 16Division of Breast Cancer Research, The Institute of Cancer
Research, London, UK. 17Department of Pathology, Harvard Medical School,
Boston, MA, USA. 18Department of Surgery, Umeå University Hospital, Umeå,
Sweden.
Received: 20 November 2018 Accepted: 5 March 2019
References
1. U.S. Preventive Services Task Force. Screening for breast cancer: U.S.
Preventive Services Task Force recommendation statement. Ann Intern
Med. 2009;151(10):716–26.
2. Smith R, Cokkinides V, Brooks D, Saslow D, Brawley O. Cancer screening in
the United States, 2010: a review of current American Cancer Society
guidelines and issues in cancer screening. Ca. 2010;60(2):99–119.
3. Hauk L. Practice guidelines: American College of Obstetricians and
Gynecologists updates Breast Cancer screening guidelines. Am Fam
Physician. 2012;85:654–5.
4. American College of Obstetricians and gynecologists. Practice bulletin no.
122: breast cancer screening. Obstet Gynecol. 2011;118:372–82.
5. Klabunde CN, Ballard-Barbash R. Evaluating population-based screening
mammography programs internationally. Semin Breast Dis. 2007;10(2):102–7.
6. Schopper D, de Wolf C. How effective are breast cancer screening programmes
by mammography? Review of the current evidence. Eur J Cancer. 2009;45(11):
1916–23.
7. Oeffinger KC, Fontham EH, Etzioni R, et al. Breast cancer screening for
women at average risk: 2015 guideline update from the American
Cancer Society. JAMA. 2015;314(15):1599–614.
8. Gail MH, Costantino JP, Bryant J, Croyle R, Freedman L, Helzlsouer K, Vogel
V. Weighing the risks and benefits of tamoxifen treatment for preventing
breast cancer. J Natl Cancer Inst. 1999;91(21):1829–46.
9. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin
WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, et al. Tamoxifen for prevention
of breast cancer: report of the National Surgical Adjuvant Breast and Bowel
Project P-1 Study. J Natl Cancer Inst. 1998;90(18):1371–88.
10. Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN,
Bevers TB, Fehrenbacher L, Pajon ER Jr, Wade JL 3rd, et al. Effects of tamoxifen
vs raloxifene on the risk of developing invasive breast cancer and other
disease outcomes: the NSABP study of tamoxifen and raloxifene (STAR) P-2
trial. JAMA. 2006;295(23):2727–41.
11. Visvanathan K, Chlebowski RT, Hurley P, Col NF, Ropka M, Collyar D, Morrow
M, Runowicz C, Pritchard KI, Hagerty K, et al. American society of clinical
oncology clinical practice guideline update on the use of pharmacologic
interventions including tamoxifen, raloxifene, and aromatase inhibition for
breast cancer risk reduction. J Clin Oncol. 2009;27(19):3235–58.
12. Freedman AN, Graubard BI, Rao SR, McCaskill-Stevens W, Ballard-Barbash R,
Gail MH. Estimates of the number of US women who could benefit from
tamoxifen for breast cancer chemoprevention. J Natl Cancer Inst. 2003;95(7):
526–32.
13. Visvanathan K, Hurley P, Bantug E, Brown P, Col NF, Cuzick J, Davidson NE,
DeCensi A, Fabian C, Ford L, et al. Use of pharmacologic interventions for
breast cancer risk reduction: American Society of Clinical Oncology clinical
practice guideline. J Clin Oncol. 2013;31(23):2942–62.
14. Costantino JP, Gail MH, Pee D, Anderson S, Redmond CK, Benichou J,
Wieand HS. Validation studies for models projecting the risk of invasive
and total breast cancer incidence. J Natl Cancer Inst. 1999;91:1541–8.
15. Rockhill B, Spiegelman D, Byrne C, Hunter DJ, Colditz GA. Validation of the
Gail et al. model of breast cancer risk prediction and implications for
chemoprevention. J Natl Cancer Inst. 2001;93(5):358–66.
16. Chlebowski RT, Anderson GL, Lane DS, Aragaki AK, Rohan T, Yasmeen S,
Sarto G, Rosenberg CA, Hubbell FA, Investigators FtWsHI. Predicting risk of
breast cancer in postmenopausal women by hormone receptor status.
J Natl Cancer Inst. 2007;99(22):1695–705.
17. Bondy ML, Vogel VG. Re: validation of the Gail et al. model for predicting
individual breast cancer risk. J Natl Cancer Inst. 1994;86(17):1350.
Clendenen et al. Breast Cancer Research           (2019) 21:42 Page 10 of 12
18. Pankratz VS, Hartmann LC, Degnim AC, Vierkant RA, Ghosh K, Vachon CM,
Frost MH, Maloney SD, Reynolds C, Boughey JC. Assessment of the accuracy
of the Gail model in women with atypical hyperplasia. J Clin Oncol. 2008;
26(33):5374–9.
19. Pfeiffer RM, Park Y, Kreimer AR, Lacey JV, Pee D, Greenlee RT, Buys SS,
Hollenbeck A, Rosner B, Gail MH, et al. Risk prediction for breast,
endometrial, and ovarian cancer in White women aged 50 y or older:
derivation and validation from population-based cohort studies. PLoS
Med. 2013;10(7):e1001492.
20. Decarli A, Calza S, Masala G, Specchia C, Palli D, Gail MH. Gail model for
prediction of absolute risk of invasive breast cancer: independent evaluation
in the Florence–European prospective investigation into Cancer and Nutrition
Cohort. J Natl Cancer Inst. 2006;98(23):1686–93.
21. Matsuno RK, Costantino JP, Ziegler RG, Anderson GL, Li H, Pee D, Gail MH.
Projecting individualized absolute invasive breast cancer risk in Asian and
Pacific Islander American women. J Natl Cancer Inst. 2011;103(12):951–61.
22. Gail MH, Costantino JP, Pee D, Bondy M, Newman L, Selvan M, Anderson
GL, Malone KE, Marchbanks PA, McCaskill-Stevens W, et al. Projecting
individualized absolute invasive breast cancer risk in African American women.
J Natl Cancer Inst. 2007;99(23):1782–92.
23. Schonfeld SJ, Pee D, Greenlee RT, Hartge P, Lacey JV Jr, Park Y, Schatzkin A,
Visvanathan K, Pfeiffer RM. Effect of changing breast cancer incidence rates
on the calibration of the Gail model. J Clin Oncol. 2010;28(14):2411–7.
24. Ge W, Clendenen TV, Afanasyeva Y, Koenig KL, Agnoli C, Brinton LA, Dorgan JF,
Eliassen AH, Falk RT, Hallmans G, et al. Circulating anti-Mullerian hormone and
breast cancer risk: a study in ten prospective cohorts. Int J Cancer. 2018;
142(11):2215–26.
25. Zeleniuch-Jacquotte A, Afanasyeva Y, Kaaks R, Rinaldi S, Scarmo S, Liu M,
Arslan AA, Toniolo P, Shore RE, Koenig KL. Premenopausal serum androgens
and breast cancer risk: a nested case-control study. Breast Cancer Res. 2012;
14(1):R32.
26. Micheli A, Muti P, Secreto G, Krogh V, Meneghini E, Venturelli E, Sieri S, Pala
V, Berrino F. Endogenous sex hormones and subsequent breast cancer in
premenopausal women. Int J Cancer. 2004;112(2):312–8.
27. Kaaks R, Berrino F, Key T, Rinaldi S, Dossus L, Biessy C, Secreto G, Amiano P,
Bingham S, Boeing H, et al. Serum sex steroids in premenopausal women
and breast cancer risk within the European Prospective Investigation into
Cancer and Nutrition (EPIC). J Natl Cancer Inst. 2005;97(10):755–65.
28. Eliassen AH, Missmer SA, Tworoger SS, Spiegelman D, Barbieri RL, Dowsett
M, Hankinson SE. Endogenous steroid hormone concentrations and risk of
breast cancer among premenopausal women. J Natl Cancer Inst. 2006;
98(19):1406–15.
29. Dorgan JF, Stanczyk FZ, Kahle LL, Brinton LA. Prospective case-control study
of premenopausal serum estradiol and testosterone levels and breast cancer
risk. Breast Cancer Res. 2010;12(6):R98.
30. Kaaks R, Tikk K, Sookthai D, Schock H, Johnson T, Tjonneland A, Olsen A,
Overvad K, Clavel-Chapelon F, Dossus L, et al. Premenopausal serum sex
hormone levels in relation to breast cancer risk, overall and by hormone
receptor status - results from the EPIC cohort. Int J Cancer. 2014;134(8):
1947–57.
31. Key T, Appleby P, Barnes I, Reeves G, Endogenous H, Breast Cancer
Collaborative G. Endogenous sex hormones and breast cancer in
postmenopausal women: reanalysis of nine prospective studies. J Natl
Cancer Inst. 2002;94(8):606–16.
32. Zeleniuch-Jacquotte A, Shore RE, Koenig KL, Akhmedkhanov A, Afanasyeva
Y, Kato I, Kim MY, Rinaldi S, Kaaks R, Toniolo P. Postmenopausal levels of
oestrogen, androgen, and SHBG and breast cancer: long-term results of a
prospective study. Br J Cancer. 2004;90(1):153–9.
33. Manjer J, Johansson R, Berglund G, Janzon L, Kaaks R, Agren A, Lenner P.
Postmenopausal breast cancer risk in relation to sex steroid hormones,
prolactin and SHBG (Sweden). Cancer Causes Control. 2003;14(7):599–607.
34. Kaaks R, Rinaldi S, Key TJ, Berrino F, Peeters PH, Biessy C, Dossus L, Lukanova A,
Bingham S, Khaw KT, et al. Postmenopausal serum androgens, oestrogens and
breast cancer risk: the European prospective investigation into cancer and
nutrition. Endocr Relat Cancer. 2005;12(4):1071–82.
35. Baglietto L, Severi G, English DR, Krishnan K, Hopper JL, McLean C, Morris
HA, Tilley WD, Giles GG. Circulating steroid hormone levels and risk of
breast cancer for postmenopausal women. Cancer Epidemiol Biomarkers
Prev. 2010;19(2):492–502.
36. Farhat GN, Cummings SR, Chlebowski RT, Parimi N, Cauley JA, Rohan TE,
Huang AJ, Vitolins M, Hubbell FA, Manson JE, et al. Sex hormone levels and
risks of estrogen receptor-negative and estrogen receptor-positive breast
cancers. J Natl Cancer Inst. 2011;103(7):562–70.
37. Zhang X, Tworoger SS, Eliassen AH, Hankinson SE. Postmenopausal plasma
sex hormone levels and breast cancer risk over 20 years of follow-up. Breast
Cancer Res Treat. 2013;137(3):883–92.
38. Sieri S, Krogh V, Bolelli G, Abagnato CA, Grioni S, Pala V, Evangelista A,
Allemani C, Micheli A, Tagliabue G, et al. Sex hormone levels, breast
cancer risk, and cancer receptor status in postmenopausal women: the
ORDET cohort. Cancer Epidemiol Biomarkers Prev. 2009;18(1):169–76.
39. Eliassen AH, Zeleniuch-Jacquotte A, Rosner B, Hankinson SE. Plasma anti-
Mullerian hormone concentrations and risk of breast cancer among
premenopausal women in the Nurses' Health Studies. Cancer Epidemiol
Biomarkers Prev. 2016;25(5):854–60.
40. van Rooij IA, Broekmans FJ, Scheffer GJ, Looman CW, Habbema JD, de
Jong FH, Fauser BJ, Themmen AP, te Velde ER. Serum antimullerian
hormone levels best reflect the reproductive decline with age in
normal women with proven fertility: a longitudinal study. Fertil Steril.
2005;83(4):979–87.
41. Dorgan JF, Spittle CS, Egleston BL, Shaw CM, Kahle LL, Brinton LA. Assay
reproducibility and within-person variation of Mullerian inhibiting substance.
Fertil Steril. 2010;94(1):301–4.
42. Missmer SA, Spiegelman D, Bertone-Johnson ER, Barbieri RL, Pollak MN,
Hankinson SE. Reproducibility of plasma steroid hormones, prolactin, and
insulin-like growth factor levels among premenopausal women over a 2- to
3-year period. Cancer Epidemiol Biomarkers Prev. 2006;15(5):972–8.
43. de Kat AC, van der Schouw YT, Eijkemans MJ, Herber-Gast GC, Visser JA,
Verschuren WM, Broekmans FJ. Back to the basics of ovarian aging: a
population-based study on longitudinal anti-Mullerian hormone decline.
BMC Med. 2016;14(1):151.
44. La Marca A, Spada E, Grisendi V, Argento C, Papaleo E, Milani S, Volpe A.
Normal serum anti-Mullerian hormone levels in the general female
population and the relationship with reproductive history. Eur J Obstet
Gynecol Reprod Biol. 2012;163(2):180–4.
45. Schoemaker MJ, Folkerd EJ, Jones ME, Rae M, Allen S, Ashworth A, Dowsett
M, Swerdlow AJ. Combined effects of endogenous sex hormone levels and
mammographic density on postmenopausal breast cancer risk: results from
the Breakthrough Generations Study. Br J Cancer. 2014;110(7):1898–907.
46. Thomas HV, Key TJ, Allen DS, Moore JW, Dowsett M, Fentiman IS, Wang DY.
A prospective study of endogenous serum hormone concentrations and
breast cancer risk in premenopausal women on the island of Guernsey. Br J
Cancer. 1997;75(7):1075–9.
47. Nichols HB, Baird DD, Stanczyk FZ, Steiner AZ, Troester MA, Whitworth KW,
Sandler DP. Anti-Mullerian hormone concentrations in premenopausal
women and breast cancer risk. Cancer Prev Research (Phila). 2015;8(6):528-
34.
48. Fortner RT, Eliassen AH, Spiegelman D, Willett WC, Barbieri RL, Hankinson SE.
Premenopausal endogenous steroid hormones and breast cancer risk:
results from the Nurses' Health Study II. Breast Cancer Res. 2013;15(2):R19.
doi:10.1186/bcr3394.
49. Bruzzi P, Green SB, Byar DP, Brinton LA, Schairer C. Estimating the population
attributable risk for multiple risk factors using case-control data. Am J
Epidemiol. 1985;122(5):904–14.
50. USA: National Center for Health Statistics, Centers for Disease Control and
Prevention. https://www.cdc.gov/nchs/data_access/cmf.htm. Accessed 17
July 2018.
51. Chen J, Pee D, Ayyagari R, Graubard B, Schairer C, Byrne C, Benichou J, Gail MH.
Projecting absolute invasive breast cancer risk in white women with a model
that includes mammographic density. J Natl Cancer Inst. 2006;98(17):1215–26.
52. Anothaisintawee T, Teerawattananon Y, Wiratkapun C, Kasamesup V,
Thakkinstian A. Risk prediction models of breast cancer: a systematic
review of model performances. Breast Cancer Res Treat. 2012;133(1):1–10.
53. Tworoger SS, Zhang X, Eliassen AH, Qian J, Colditz GA, Willett WC, Rosner
BA, Kraft P, Hankinson SE. Inclusion of endogenous hormone levels in risk
prediction models of postmenopausal breast cancer. J Clin Oncol. 2014;
32(28):3111–7.
54. Wacholder S, Hartge P, Prentice R, Garcia-Closas M, Feigelson HS, Diver WR,
Thun MJ, Cox DG, Hankinson SE, Kraft P, et al. Performance of common
genetic variants in breast-cancer risk models. N Engl J Med. 2010;362(11):
986–93.
55. Barlow WE, White E, Ballard-Barbash R, Vacek PM, Titus-Ernstoff L, Carney PA,
Tice JA, Buist DS, Geller BM, Rosenberg R, et al. Prospective breast cancer
Clendenen et al. Breast Cancer Research           (2019) 21:42 Page 11 of 12
risk prediction model for women undergoing screening mammography.
J Natl Cancer Inst. 2006;98(17):1204–14.
56. Hüsing A, Fortner RT, Kühn T, Overvad K, Tjønneland A, Olsen A, Boutron-
Ruault M-C, Severi G, Fournier A, Boeing H, et al. Added value of serum
hormone measurements in risk prediction models for breast cancer for
women not using exogenous hormones: results from the EPIC cohort. Clin
Cancer Res. 2017;
57. Mackarem G, Roche CA, Hughes KS. The effectiveness of the Gail model in
estimating risk for development of breast cancer in women under 40 years
of age. Breast J. 2001;7(1):34–9.
58. Dartois L, Gauthier É, Heitzmann J, Baglietto L, Michiels S, Mesrine S,
Boutron-Ruault M-C, Delaloge S, Ragusa S, Clavel-Chapelon F, et al. A
comparison between different prediction models for invasive breast
cancer occurrence in the French E3N cohort. Breast Cancer Res Treat.
2015;150(2):415–26.
59. Dite GS, MacInnis RJ, Bickerstaffe A, Dowty JG, Allman R, Apicella C, Milne
RL, Tsimiklis H, Phillips KA, Giles GG, et al. Breast cancer risk prediction using
clinical models and 77 independent risk-associated SNPs for women aged
under 50 years: Australian Breast Cancer Family Registry. Cancer Epidemiol
Biomarkers Prev. 2016;25(2):359–65.
60. Ueda K, Tsukuma H, Tanaka H, Ajiki W, Oshima A. Estimation of individualized
probabilities of developing breast cancer for Japanese women. Breast Cancer.
2003;10(1):54–62.
61. Lukanova A, Lundin E, Zeleniuch-Jacquotte A, Muti P, Mure A, Rinaldi S,
Dossus L, Micheli A, Arslan A, Lenner P, et al. Body mass index, circulating
levels of sex-steroid hormones, IGF-I and IGF-binding protein-3: a cross-
sectional study in healthy women. Eur J Endocrinol. 2004;150(2):161–71.
62. Shaw CM, Stanczyk FZ, Egleston BL, Kahle LL, Spittle CS, Godwin AK, Brinton
LA, Dorgan JF. Serum antimullerian hormone in healthy premenopausal
women. Fertil Steril. 2011;95(8):2718–21.
63. Nichols HB, Baird DD, Stanczyk FZ, Steiner AZ, Troester MA, Whitworth KW,
Sandler DP. Anti-Mullerian hormone concentrations in premenopausal
women and breast cancer risk. Cancer Prev Res (Phila). 2015;8(6):528–34.
64. Dorgan JF, Stanczyk FZ, Egleston BL, Kahle LL, Shaw CM, Spittle CS, Godwin
AK, Brinton LA. Prospective case-control study of serum mullerian inhibiting
substance and breast cancer risk. J Natl Cancer Inst. 2009;101(21):1501–9.
65. Tice JA, Cummings SR, Ziv E, Kerlikowske K. Mammographic breast density
and the Gail model for breast cancer risk prediction in a screening population.
Breast Cancer Res Treat. 2005;94(2):115–22.
66. Tice JA, Cummings SR, Smith-Bindman R, Ichikawa L, Barlow WE, Kerlikowske K.
Using clinical factors and mammographic breast density to estimate breast
cancer risk: development and validation of a new predictive model. Ann Intern
Med. 2008;148(5):337–47.
67. Endogenous H, Breast Cancer Collaborative G, Key TJ, Appleby PN, Reeves
GK, Travis RC, Alberg AJ, Barricarte A, Berrino F, Krogh V, et al. Sex hormones
and risk of breast cancer in premenopausal women: a collaborative reanalysis
of individual participant data from seven prospective studies. Lancet Oncol.
2013;14(10):1009–19.
68. Mealiffe ME, Stokowski RP, Rhees BK, Prentice RL, Pettinger M, Hinds DA.
Assessment of clinical validity of a breast cancer risk model combining
genetic and clinical information. J Natl Cancer Inst. 2010;102(21):1618–27.
69. Gail MH. Discriminatory accuracy from single-nucleotide polymorphisms in
models to predict breast cancer risk. J Natl Cancer Inst. 2008;100(14):1037–41.
70. Dite GS, Mahmoodi M, Bickerstaffe A, Hammet F, Macinnis RJ, Tsimiklis H,
Dowty JG, Apicella C, Phillips KA, Giles GG, et al. Using SNP genotypes to
improve the discrimination of a simple breast cancer risk prediction model.
Breast Cancer Res Treat. 2013;139(3):887–96.
71. Allman R, Dite GS, Hopper JL, Gordon O, Starlard-Davenport A, Chlebowski
R, Kooperberg C. SNPs and breast cancer risk prediction for African
American and Hispanic women. Breast Cancer Res Treat. 2015;154(3):583–9.
72. Darabi H, Czene K, Zhao W, Liu J, Hall P, Humphreys K. Breast cancer risk
prediction and individualised screening based on common genetic variation
and breast density measurement. Breast Cancer Res. 2012;14(1):R25.
73. Lee CP, Choi H, Soo KC, Tan MH, Chay WY, Chia KS, Liu J, Li J, Hartman M.
Mammographic breast density and common genetic variants in breast
cancer risk prediction. PLoS One. 2015;10(9):e0136650.
74. McCarthy AM, Armstrong K, Handorf E, Boghossian L, Jones M, Chen J,
Demeter MB, McGuire E, Conant EF, Domchek SM. Incremental impact of
breast cancer SNP panel on risk classification in a screening population of
white and African American women. Breast Cancer Res Treat. 2013;138(3):
889–98.
75. Husing A, Canzian F, Beckmann L, Garcia-Closas M, Diver WR, Thun MJ, Berg
CD, Hoover RN, Ziegler RG, Figueroa JD, et al. Prediction of breast cancer
risk by genetic risk factors, overall and by hormone receptor status. J Med
Genet. 2012;49(9):601–8.
76. Ganna A, Reilly M, de Faire U, Pedersen N, Magnusson P, Ingelsson E. Risk
prediction measures for case-cohort and nested case-control designs: an
application to cardiovascular disease. Am J Epidemiol. 2012;175(7):715–24.
77. Samuelsen S. A pseudolikelihood approach to analysis of nested case-control
studies. Biometrika. 1997;84(2):379–94.
78. Jung S, Allen N, Arslan AA, Baglietto L, Brinton LA, Egleston BL, Falk R,
Fortner RT, Helzlsouer KJ, Idahl A, et al. Demographic, lifestyle, and other
factors in relation to anti-Müllerian hormone levels in mostly late premenopausal
women. Fertil Steril. 2017;107(4):1012–1022.e1012.
79. Birch Petersen K, Hvidman HW, Forman JL, Pinborg A, Larsen EC, Macklon
KT, Sylvest R, Andersen AN. Ovarian reserve assessment in users of oral
contraception seeking fertility advice on their reproductive lifespan. Hum
Reprod. 2015;30(10):2364–75.
80. Gail MH. Twenty-five years of breast cancer risk models and their
applications. J Natl Cancer Inst. 2015;107(5):djv042.
81. Garcia-Closas M, Gunsoy NB, Chatterjee N. Combined associations of
genetic and environmental risk factors: implications for prevention of breast
cancer. J Natl Cancer Inst. 2014;106(11):dju305.
Clendenen et al. Breast Cancer Research           (2019) 21:42 Page 12 of 12
